Risk factors
Inhibrx Biosciences (INBX) risk factors
Item 1A of every Inhibrx Biosciences, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
80 risks, 10 new, 7 dropped, 17 reworded since the prior year. Inhibrx Biosciences faces commercialization risks for ozekibart in chondrosarcoma without prior marketing experience.
Filed Mar 19, 2026 - FY2024 10-K risk factors
77 risks. Clinical-stage biotechnology company with no product revenue, relying entirely on external financing and collaborations for drug development.
Filed Mar 17, 2025